Clinigen, the global speciality pharmaceutical services group, today announced that Equity Pharmaceuticals, part of the Clinigen Group, has entered into a new collaboration with Servier, an ...

The ALTAIR trial ultimately showed negative results in its question of whether adding trifluridine/tipiracil (TAS-102) would improve outcomes as compared with placebo in patients who were ctDNA or ...